Skip to main content
Clinical Trials/NL-OMON47612
NL-OMON47612
Completed
Phase 4

Advancing addiction treatment using neuromodulation: a rTMS enhanced CBT trial - Advancing addiction treatment

Academisch Medisch Centrum0 sites80 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
alcoholverslaving
Sponsor
Academisch Medisch Centrum
Enrollment
80
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • The recruitment of participants will take place as follows. Practitioners at
  • Jellinek will inform patients about our study and we will give presentations at
  • Jellinek to inform patients about this study. If somebody is willing to
  • participate in the study, we will personally visit them at Jellinek and explain
  • the entire procedure. Furthermore they will receive an information letter by
  • email to make sure they can read the information again carefully. If they are
  • still interested in participation they will sign informed consent and we will
  • perform screening for inclusion and exclusion criteria. Demographics,
  • psychiatric disorders (MINI), TMS contraindications and MR contraindications
  • are questioned to make sure that the individual can participate.

Exclusion Criteria

  • Exclusion criteria
  • \- A DSM\-V diagnosis of schizophrenia or another psychotic disorder, personality
  • disorder or sleep disorder.
  • \- TMS contraindications: history of epileptic seizures or epilepsy in a first
  • degree relative, irregular sleep/ wake rhythm.
  • \- MR contraindications (only relevant for the 40 participants who will undergo
  • MR scanning): metal implants, claustrophobia.

Outcomes

Primary Outcomes

Not specified

Similar Trials